Hamps Bio Limited (BOM:544312)
26.25
0.00 (0.00%)
At close: Jul 7, 2026
Hamps Bio Revenue
In the fiscal year ending March 31, 2026, Hamps Bio had annual revenue of 84.75M INR with 27.08% growth. Hamps Bio had revenue of 44.83M in the half year ending March 31, 2026.
Revenue
84.75M
Revenue Growth
+27.08%
P/S Ratio
2.70
Revenue / Employee
n/a
Employees
75
Market Cap
228.69M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 84.75M | 18.06M | 27.08% |
| Mar 31, 2025 | 66.69M | 1.94M | 2.99% |
| Mar 31, 2024 | 64.75M | 8.97M | 16.08% |
| Mar 31, 2023 | 55.78M | 2.38M | 4.45% |
| Mar 31, 2022 | 53.40M | 15.18M | 39.71% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Welcure Drugs and Pharmaceuticals | 3.66B |
| Add-Shop E-Retail | 1.55B |
| Deccan Health Care | 819.05M |
| Panjon | 476.21M |
| Gujarat Terce Laboratories | 474.73M |
| Cian Healthcare | 232.80M |
| Zenith Healthcare | 105.22M |
| Norris Medicines | 81.32M |